Fantofarone | SR 33557 | CAS#114432-13-2

Fantofarone
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326888

CAS#: 114432-13-2

Description: Fantofarone, also known as SR 33557, is a highly potent calcium channel antagonist representative of a new class of slow channel blockers. Fantofarone can significantly modify cardiac function and in particular, decrease MO2C consumption during periods of elevated heart rate. Fantofarone is able to induce submaximal peripheral vasodilating effects at doses that are devoid of any clinically significant cardiac effect.

Chemical Structure

Fantofarone

CAS# 114432-13-2

Instruction

Theoretical Analysis

MedKoo Cat#: 326888
Name: Fantofarone
CAS#: 114432-13-2
Chemical Formula: C31H38N2O5S
Exact Mass: 550.25
Molecular Weight: 550.714
Elemental Analysis: C, 67.61; H, 6.96; N, 5.09; O, 14.53; S, 5.82

Price and Availability

Size	Price	Availability
50mg	USD 450	2 weeks
100mg	USD 750	2 weeks
200mg	USD 1350	2 weeks
500mg	USD 2950	2 weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: SR 33557; SR-33557; SR33557; Fantofarone

IUPAC/Chemical Name: N-(3,4-dimethoxyphenethyl)-3-(4-((2-isopropylindolizin-1-yl)sulfonyl)phenoxy)-N-methylpropan-1-amine

InChi Key: ITAMRBIZWGDOHW-UHFFFAOYSA-N

InChi Code: InChI=1S/C31H38N2O5S/c1-23(2)27-22-33-18-7-6-9-28(33)31(27)39(34,35)26-13-11-25(12-14-26)38-20-8-17-32(3)19-16-24-10-15-29(36-4)30(21-24)37-5/h6-7,9-15,18,21-23H,8,16-17,19-20H2,1-5H3

SMILES Code: CC(C1=CN2C=CC=CC2=C1S(=O)(C3=CC=C(OCCCN(CCC4=CC=C(OC)C(OC)=C4)C)C=C3)=O)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 550.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Manning A, Mouton J, Chatelain P. Fantofarone (SR 33557): effect on post- ischaemic functional recovery in perfused rat hearts. Eur J Pharmacol. 1992 Sep 22;220(2-3):249-58. doi: 10.1016/0014-2999(92)90755-s. PMID: 1425996.

2: Barthélémy G, Chatelain P, Manning A. Fantofarone (SR 33557): cardiovascular actions in anesthetized dogs. Arch Int Pharmacodyn Ther. 1994 Mar- Apr;327(2):204-19. PMID: 7979829.

3: Chatelain P, Matteazzi JR, Laruel R. Interaction of the calcium antagonist fantofarone with phospholipids: electrostatic effects. Biochem Pharmacol. 1994 Oct 7;48(7):1393-8. doi: 10.1016/0006-2952(94)90562-2. PMID: 7945438.

4: Hodeige D, Chatelain P, Manning A. Fantofarone (SR33557): effects on myocardial oxygen consumption and coronary blood flow. Pharmacology. 1994 Jan;48(1):49-55. doi: 10.1159/000139161. PMID: 8309987.

5: Dongay B, Dol-Gleizes F, Herbert JM. Effect of fantofarone, a new Ca2+ channel antagonist, on angioplasty-induced vasospasm in an atherosclerotic rabbit model. Biochem Pharmacol. 1998 Jun 15;55(12):2047-50. doi: 10.1016/s0006-2952(98)00026-4. PMID: 9714327.

6: Glasser SP, Singh SN, Humen DP. Safety and efficacy of monotherapy with fantofarone, a novel calcium channel antagonist, in patients with chronic stable angina pectoris. Fantofarone Study Group. J Clin Pharmacol. 1997 Jan;37(1):53-7. doi: 10.1177/009127009703700109. PMID: 9048273.

7: Adovelande J, Delèze J, Schrével J. Synergy between two calcium channel blockers, verapamil and fantofarone (SR33557), in reversing chloroquine resistance in Plasmodium falciparum. Biochem Pharmacol. 1998 Feb 15;55(4):433-40. doi: 10.1016/s0006-2952(97)00482-6. PMID: 9514077.

8: Chatelain P, Matteazzi JR, Laruel R. Binding of fantofarone, a novel Ca2+ antagonist, to serum albumin: a fluorescence study. J Pharm Sci. 1994 May;83(5):674-6. doi: 10.1002/jps.2600830516. PMID: 8071819.

9: Bellissant E, Giudicelli JF. Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers. Br J Clin Pharmacol. 1999 Dec;48(6):801-10. doi: 10.1046/j.1365-2125.1999.00091.x. PMID: 10594483; PMCID: PMC2014307.

10: Vander Elst L, Chatelain P, Manning AS, Laruel R, Van Haverbeke Y, Muller RN. 31P nuclear magnetic resonance study of the effects of the calcium ion channel antagonist fantofarone on the rat heart. Eur J Pharmacol. 1994 Jan 14;251(2-3):163-72. doi: 10.1016/0014-2999(94)90397-2. PMID: 8149974.

11: Romey G, Bois P, Lazdunski M. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel. Eur J Pharmacol. 1994 Sep 22;263(1-2):101-5. doi: 10.1016/0014-2999(94)90529-0. PMID: 7821341.

12: Romey G, Lazdunski M. Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1348-52. PMID: 7996445.

13: Spedding M, Kenny B, Chatelain P. New drug binding sites in Ca2+ channels. Trends Pharmacol Sci. 1995 Apr;16(4):139-42. doi: 10.1016/s0165-6147(00)89002-1. PMID: 7610500.

14: Chatelain P, Dewinkeleer P, Beaufort P, Meysmans L, Clinet M. Characterization of the binding of [3H]SR 33805 to the slow Ca2+ channel in rat heart sarcolemmal membrane. Eur J Pharmacol. 1994 Apr 15;267(2):151-60. doi: 10.1016/0922-4106(94)90166-x. PMID: 8050476.

15: Chatelain P, Mouton J, Feys G, Laruel A, Manning AS. Vascular calcium overload produced by vitamin D3, in rats. Effect of treatment with SR 33805, a novel calcium entry blocker. Cardiovasc Res. 1995 Dec;30(6):1038-43. PMID: 8746222.

16: Seumois G, Fillet M, Gillet L, Faccinetto C, Desmet C, François C, Dewals B, Oury C, Vanderplasschen A, Lekeux P, Bureau F. De novo C16- and C24-ceramide generation contributes to spontaneous neutrophil apoptosis. J Leukoc Biol. 2007 Jun;81(6):1477-86. doi: 10.1189/jlb.0806529. Epub 2007 Feb 28. PMID: 17329567.

17: Ertel SI, Clozel JP. Mibefradil (Ro 40-5967): the first selective T-type Ca2+ channel blocker. Expert Opin Investig Drugs. 1997 May;6(5):569-82. doi: 10.1517/13543784.6.5.569. PMID: 15989621.

18: Chatelain P, Clinet M, Polster P, Christophe B, Manning AS. In vitro characterization of a novel Ca2+ entry blocker: SR 33805. Eur J Pharmacol. 1993 Aug 15;246(3):181-93. doi: 10.1016/0922-4106(93)90030-d. PMID: 8223943.

19: Cazorla O, Lacampagne A, Fauconnier J, Vassort G. SR33805, a Ca2+ antagonist with length-dependent Ca2+ -sensitizing properties in cardiac myocytes. Br J Pharmacol. 2003 May;139(1):99-108. doi: 10.1038/sj.bjp.0705221. PMID: 12746228; PMCID: PMC1573823.

20: Dol F, Schaeffer P, Lamarche I, Mares AM, Chatelain P, Herbert JM. Effect of SR 33805 on arterial smooth muscle cell proliferation and neointima formation following vascular injury. Eur J Pharmacol. 1995 Jul 4;280(2):135-42. doi: 10.1016/0014-2999(95)00196-r. PMID: 7589177.

Your view history

Fantofarone featured